Cell therapy for hard-to-treat chronic graft-versus-host disease
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had a stem cell transplant from a donor (allogeneic transplant).
- You currently have active chronic graft-versus-host disease (cGVHD) that needs treatment.
- You have already tried at least two different treatments for cGVHD, and they didn't work or stopped working.
- Your blood counts and organ function (kidney, liver) are within certain minimum levels.
- You are not pregnant (if applicable) and agree to use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
This trial tests a new immune cell treatment for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard medications like ruxolitinib. The goal is to see if these special cells can calm the immune attack and help manage symptoms.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This study tests whether special cells from your donor, called Treg cells (a type of immune cell that calms inflammation), can help treat graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have already tried other treatments but still have GVHD symptoms.
This trial tests a new medicine called CK0802 for patients whose graft versus host disease (a complication after bone marrow transplant) did not improve with standard steroid treatment. The goal is to see if CK0802 can help control this condition when steroids alone haven't worked.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.